The Technical Analyst
DexCom Inc [DXCM]
Exchange: NASDAQ Sector: Healthcare Industry: Medical Devices
DexCom Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
-5.41% $130.55
America/New_York / 26 apr 2024 @ 09:55
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 50 329 mill |
| EPS: | 1.300 |
| P/E: | 100.42 |
| Earnings Date: | May 22, 2024 |
| SharesOutstanding: | 385.52 mill |
| Avg Daily Volume: | 3.09 mill |
| RATING 2024-04-25 |
|---|
| S |
| Strong Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Buy | |
| DE: | Strong Buy | |
| P/E: | Strong Buy | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | 1/24 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE 100.42 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0.45x |
| Company: PE 100.42 | industry: PE 222.16 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$29.20 (-77.64%) $-101.35 |
| Date: 2024-04-26 |
| Expected Trading Range (DAY) |
|---|
|
$ 127.20 - 135.70 ( +/- 3.23%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-15 | Dolan Matthew Vincent | Sell | 1 990 | Common Stock |
| 2024-04-08 | Sayer Kevin R | Sell | 27 272 | Common Stock |
| 2024-04-08 | Sayer Kevin R | Sell | 22 361 | Common Stock |
| 2024-03-28 | Brown Michael Jon | Sell | 2 524 | Common Stock |
| 2024-03-28 | Brown Michael Jon | Sell | 100 | Common Stock |
| INSIDER POWER |
|---|
| -3.99 |
| Last 99 transactions |
| Buy: 330 077 | Sell: 354 468 |
Forecast:
11:35 - $133.06
Live Trading Signals (every 1 min)
Forecast
1: 10:05 - $131.21
Forecast 2: 10:55 - $130.73
Forecast 3: 11:35 - $133.06
SCORE
-10.00
Sell
-10.00
Sell
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $130.55 (-5.41% ) |
| Volume | 1.362 mill |
| Avg. Vol. | 3.09 mill |
| % of Avg. Vol | 44.11 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For DXCM
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $126.59 | N/A | Active |
|---|
DXCM
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
Last 10 Buy Signals
Latest Press Releases
2024-04-25 16:03:00 - Press Release
Dexcom Reports First Quarter 2024 Financial Results
San diego--(business wire)---- $dxcm #dexcom--dexcom, inc. (nasdaq: dxcm) today reported its financial results as of and for the quarter ended march 31, 2024. first quarter 2024 financial highlights: revenue grew 24% year-over-year to $921.0 million on a reported basis and 25% year-over-year on an organic1 basis. u.s. revenue and international revenue both grew 24% on a reported basis and international revenue grew 26% on an organic1 basis, all on a year-over-year basis. gaap operating income of $101.1 million o.
2024-04-10 10:19:00 - Press Release
Md Revolution Partners With Dexcom To Integrate Continuous Glucose Monitoring Systems With Its Remote Care Management Platform
San diego--(business wire)--md revolution, the leader in remote care management solutions for health systems and multi-specialty clinics, has partnered with dexcom to integrate their industry-leading continuous glucose monitoring systems with md revolution's remote care management platform. over 537 million people globally are living with diabetes. dexcom supports this population as a global leader in real-time continuous glucose monitoring. dexcom's wearable devices pair with a user's smartpho.
2024-04-03 09:00:00 - Press Release
Dexcom Publishes Annual Sustainability Report
San diego--(business wire)--dexcom, inc. (nasdaq:dxcm), the leader in real-time continuous glucose monitoring (cgm) for people with diabetes, today released its annual sustainability report. this report provides updates on key corporate sustainability initiatives that are aligned with dexcom's core values and business strategy. “we are always working to advance the interests of our stakeholders, including our global customer base, employees and their families, caregivers, our communities, and o.
2024-04-02 08:30:00 - Press Release
Dexcom Schedules First Quarter 2024 Earnings Release And Conference Call For April 25, 2024 At 4:30 P.m. Eastern Time
San diego--(business wire)--dexcom, inc. (nasdaq:dxcm) today announced that it plans to release its first quarter 2024 financial results after market close on thursday, april 25, 2024. management will hold a conference call to review the company's first quarter 2024 performance starting at 4:30 p.m. (eastern time) on the same day. the conference call will be concurrently webcast. the link to the webcast will be available on the dexcom investor relations website at investors.dexcom.com and will.
2024-03-05 16:26:00 - Press Release
Stelo By Dexcom First Glucose Biosensor To Be Cleared By Fda As Over-the-counter
San diego--(business wire)--dexcom, inc. (nasdaq:dxcm), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today that the fda has cleared stelo by dexcom – the first glucose biosensor that doesn't require a prescription. there are approximately 25 million people in the u.s. living with type 2 diabetes who do not use insulin and who can benefit from continuous glucose monitoring (cgm) technology. today, dexcom g7 is available for them with a prescrip.
Latest News
2024-04-26 08:30:17 - Zacks Investment Research
DexCom (DXCM) Q1 Earnings Beat, Strong CGM Demand Continues
DexCom's (DXCM) first-quarter 2024 results reflect strong domestic and international revenue growth on the back of its real-time Continuous Glucose Monitoring system.
2024-04-25 19:36:08 - Seeking Alpha
DexCom, Inc. (DXCM) Q1 2024 Earnings Call Transcript
DexCom, Inc. (NASDAQ:DXCM ) Q1 2024 Earnings Conference Call April 25, 2024 4:30 PM ET Company Participants Sean Christensen - Vice President of Finance, and Investor Relations Kevin Sayer - Chairman, President, and Chief Executive Officer Jereme Sylvain - Chief Financial Officer Conference Call Participants Danielle Antalffy - UBS Securities Robbie Marcus - J.P. Morgan Larry Biegelsen - Wells Fargo Joanne Wuensch - Citibank Jeff Johnson - Robert W.
2024-04-25 19:01:30 - Zacks Investment Research
DexCom (DXCM) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
While the top- and bottom-line numbers for DexCom (DXCM) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
2024-04-24 10:32:03 - Zacks Investment Research
Wall Street Bulls Look Optimistic About DexCom (DXCM): Should You Buy?
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
2024-04-22 10:22:24 - Zacks Investment Research
Ahead of DexCom (DXCM) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Beyond analysts' top -and-bottom-line estimates for DexCom (DXCM), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2024.
2024-04-18 09:31:10 - Zacks Investment Research
Reasons to Retain DexCom (DXCM) Stock in Your Portfolio for Now
DexCom (DXCM) continues to raise optimism among investors, owing to its strong product portfolio.
2024-04-15 12:21:06 - Zacks Investment Research
3 Medical Instruments Stocks to Buy Amid Improving Industry Trends
The Zacks Medical - Instruments industry is expected to gain from the rising adoption of smart healthcare options, including genAI. However, supply issues and staffing shortages continue to disrupt growth.
2024-04-15 11:56:14 - Zacks Investment Research
DexCom (DXCM), MD Revolution Unite to Boost Diabetes Management
DexCom (DXCM) and MD Revolution collaborate to integrate Dexcom's continuous glucose monitoring systems with MD Revolution's remote care management platform to boost remote diabetes management.
2024-04-11 14:22:30 - Schwab Network
SLB, DXCM, CRH: The Economy is Relatively Healthy
Economic trends and earnings continue to drive most of the conversations, notes Tyler Ellegard. He discusses the impact upcoming earnings could have on the markets.
2024-04-11 10:46:34 - Zacks Investment Research
Is DexCom (DXCM) Outperforming Other Medical Stocks This Year?
Here is how DexCom (DXCM) and Anika Therapeutics (ANIK) have performed compared to their sector so far this year.